Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics

Alimentary Pharmacology and Therapeutics

Volumn 27, Issue 11, 2008, Pages 1081-1085

  Tekin, F ^a   Gunsar, F ^a   Karasu, Z ^a   Akarca, U ^a   Ersoz, G ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; ASCITES; CLINICAL ARTICLE; DECOMPENSATED LIVER CIRRHOSIS; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; PRIORITY JOURNAL; SEPSIS; URINARY TRACT INFECTION;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREOPERATIVE CARE; RIBAVIRIN; STATISTICS AS TOPIC; TREATMENT OUTCOME;

EID: 42949108594     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03680.x     Document Type: Article

References (14)

1. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996 334 : 815 20.
2. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV infected liver transplant recipients. Hepatology 2002 36 : 202 10.
3. Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992 103 : 317 22.
4. Shakil AO, McGuire B, Crippin J, et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002 36 : 1253 8.
5. Samuel D, Bizollon T, Feray C, et al. Interferon alpha-2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomize study. Gastroenterology 2003 124 : 642 50.
6. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002 8 : 350 5.
7. Forns X, Garcia-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003 39 : 389 96.
8. Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel DH. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003 9 : 905 15.
9. Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005 42 : 255 62.
10. Amarapurkar DN, Patel ND, Kamani P. Antiviral therapy of decompensated cirrhosis due to hepatitis C viral infection. Trop Gastroenterol 2005 26 : 119 22.
11. Wiesner RH, Sorrell M, Villamil F. The International Liver Transplantation Society Expert. Report of the first International Liver Transplantation Society Expert Panel Consensus Conference on liver transplantation and hepatitis C. Liver Transpl 2003 9 : S1 9.
12. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001 358 : 958 65.
13. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000 343 : 1673 80.
14. Iacobellis A, Siciliano M, Perri F, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007 46 : 206 12.